Lumos Diagnostics Holdings Ltd has released a press release.
LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study
Filed with ASX ·
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call6ix hasn’t read this filing yet.
Lumos Diagnostics Holdings Ltd. on 6ix
In the deck
Story so far
Earlier from Lumos Diagnostics
- FY25 Appendix 4E
- Lumos Announces FebriDx CLIA Waiver Application Submission
- Lumos Signs Binding Term Sheet for A$5M Loan Facility
- Reinstatement to Quotation
- Lumos Signs Pivotal US FebriDx Agreement
Later from Lumos Diagnostics
- Lumos secures follow-on PKU contract with Aptatek
- Lumos Secures 100% US Medicare Reimbursement for FebriDx
- Quarterly Activities/Appendix 4C Cash Flow Report
- Lumos Completes Enrolment Milestone for Paediatric Study
- Appendix 4D and Half Year Report
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics